Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (445)	10/8/2001 9:35:24 AM
From: tuck	Read Replies (1) \| Respond to of 1005

CIPH also makes a deal: >>FREMONT, Calif., Oct. 8 /PRNewswire/ -- Ciphergen Biosystems, Inc. (Nasdaq: CIPH - news) announced today that it has entered into a collaboration with Pfizer Inc. (NYSE: PFE - news) designed to discover proteins in serum from rat models as well as to evaluate the relative importance and utility of such proteins as biomarkers associated with drug safety. Financial and other terms of the agreement were not disclosed. ``This innovative predictive toxicology study will be carried out through our Biomarker Centers(TM),'' commented William Rich, President and CEO of Ciphergen. ``If the collaboration is successful, we expect to expand the initial body of work into an even larger program.'' One of the major bottlenecks facing the pharmaceutical industry today is the proper selection of compounds for advancement into clinical trials, where the cost of failure is enormous. There is a strong industry desire to expand the number of good toxicology models that can be used to enhance the safety and understanding of development candidates during the early phases of drug discovery. Ciphergen is at the forefront of companies engaged in assisting clients to identify alternative predictive drug toxicity methods based on its ProteinChip System and Arrays. The ProteinChip System allows one to rapidly identify multiple protein biomarkers and biomarker patterns, in animal and cell culture models, that would be predictive of likely toxicity problems. Multiple Ciphergen customers are already using the ProteinChip System in-house in pre-clinical drug development, including AstraZeneca, BASF, GlaxoSmithKline, Merck KGaA, Novartis, Pfizer and Pharmacia. Ciphergen's Biomarker Centers, located in California, Pennsylvania and Denmark, are designed to provide a valuable outsourcing service for clients who would like to leverage the experience and expertise of Ciphergen's scientific staff to accelerate their own pre-clinical and clinical drug development efforts.<< snip Cheers, Tuck